Breast Cancer News and Research

Latest Breast Cancer News and Research

Eisai's eribulin mesylate improves median OS compared with TPC in pre-treated metastatic breast cancer patients

Results of a Phase III study presented today at the American Society of Clinical Oncology (ASCO) Annual Meeting showed that Eisai's eribulin mesylate significantly improved median overall survival (OS) compared with Treatment of Physician's Choice (TPC) in heavily pre-treated metastatic breast cancer patients.

7 Jun 2010

Bisphosphonates may cause poorer survival rate in women with early stage breast cancer: Study

Scientists from the Barbara Ann Karmanos Cancer Institute in Detroit presented preliminary data that shows nitrogen-containing bisphosphonates, therapeutic agents used to promote bone health and inhibit resorption, may cause a slightly poorer survival rate in post-menopausal women with early stage breast cancer who take them for their anti-osteoporosis properties.

7 Jun 2010

bioTheranostics presents positive outcomes from CancerTYPE ID, Breast Cancer Index clinical studies

bioTheranostics, a bioMerieux company that develops innovative oncology diagnostic tests to drive personalized treatment, reported today findings from clinical studies utilizing the company's CancerTYPE ID® and Breast Cancer Index® molecular oncology tests. Data from the studies were presented this week at the American Society of Clinical Oncology (ASCO) 2010 Annual Meeting in Chicago.

7 Jun 2010

Incyte presents additional results from INCB7839 Phase I/II trial for HER2-positive metastatic breast cancer

Incyte Corporation announced today additional positive results from an ongoing Phase I/II clinical trial for its selective oral sheddase inhibitor, INCB7839, involving 66 patients with HER2-positive metastatic breast cancer during a poster session at the American Society of Clinical Oncology (ASCO) meeting in Chicago, IL, June 4 to June 8, 2010.

7 Jun 2010

Celldex Therapeutics reports mature data from CDX-011 Phase 1/2 study in advanced breast cancer

Celldex Therapeutics, Inc. today announced that mature results from a Phase 1/2 study evaluating CDX-011 in advanced stage breast cancer patients were presented at the 46th Annual Meeting of the American Society of Clinical Oncology (ASCO). CDX-011 is an experimental antibody-drug conjugate (ADC) directed against glycoprotein NMB (GPNMB) and linked to a potent cancer cell-killing drug, monomethyl-auristatin E (MMAE).

7 Jun 2010

Phase Ib/II trial data for trastuzumab-DM1 in combination with pertuzumab presented at ASCO 2010

ImmunoGen, Inc., a biopharmaceutical company that develops targeted anticancer therapeutics, today announced the presentation of clinical data from a Phase Ib/II trial conducted by Roche and Genentech to investigate the safety and preliminary efficacy of trastuzumab-DM1 (T-DM1) used in combination with Roche's investigational antibody, pertuzumab.

7 Jun 2010

Positive results from new analyses of denosumab Phase 3 trials

Amgen today announced positive results from several new analyses of two Phase 3 trials studying denosumab compared with Zometa® (zoledronic acid), the current standard of care, for the treatment of bone metastases in patients with advanced breast cancer ("136 study") and solid tumors or multiple myeloma ("244 study"). Results from these trials reinforce denosumab's consistent ability to delay the complications of bone metastases in patients with advanced cancer. These results are being presented during the 2010 American Society of Clinical Oncology Annual Meeting in Chicago.

5 Jun 2010

Multiple study data on Agendia's MammaPrint, BluePrint, and ColoPrint assays to be presented at 2010 ASCO

Agendia, a world leader in molecular cancer diagnostics, today announced that researchers from Agendia and leading academic centers in the U.S. and Europe will present data from multiple studies concerning Agendia's assays MammaPrint(R), BluePrint(TM), and ColoPrint(TM) at the American Society of Clinical Oncology Annual Meeting, June 4 - 8, 2010, at McCormick Place in Chicago. MammaPrint, the company's lead product, is the only FDA-cleared breast cancer recurrence test.

5 Jun 2010

New clinical research findings on oncology to be highlighted at ASCO 2010

Researchers from University Hospitals Case Medical Center's Ireland Cancer Center will present new clinical research findings at the 46th Annual Meeting of The American Society of Clinical Oncology June 4-8 in Chicago.

5 Jun 2010

USC to present promising new findings in cancer research at 2010 ASCO

Faculty at the University of Southern California (USC) and USC Norris Comprehensive Cancer Center will present promising new findings in a number of cancer research areas at the 2010 American Society of Clinical Oncology (ASCO) annual meeting in Chicago from June 4-8.

5 Jun 2010

Fox Chase Cancer Center announces first-in-human bi-specific HER2/HER3 pathway targeting antibody

Patients with HER2-positive cancers can have dramatic responses to HER2-targeted drugs but eventually develop resistance to the agents. With that problem in mind, Fox Chase Cancer Center researchers are testing a novel type of antibody called MM-111 in patients with HER2-positive disease who have progressed on standard therapy.

5 Jun 2010

Positive results from Phase 2, open-label ENCORE 303 trial to be presented at ASCO 2010

Syndax Pharmaceuticals, Inc., a clinical-stage epigenetics oncology company, reported final results from the Phase 2, open-label ENCORE 303 trial in post-menopausal women with advanced, estrogen receptor positive breast cancer who were progressing on aromatase inhibitor therapy.

5 Jun 2010

Bayer to present Phase I and II clinical trial data of Alpharadin in CRPC at 46th ASCO

Bayer HealthCare will present a combined analysis from Phase I and II clinical trials evaluating the safety and efficacy of one of its lead investigational cancer treatments, Alpharadin™ (radium-223 chloride), in castration-resistant prostate cancer (CRPC) that has spread to the bones (metastases).

4 Jun 2010

Infinity announces Phase 2 clinical trial results of IPI-504 for NSCLC

Infinity Pharmaceuticals, Inc. today reported the results from its Phase 2 clinical trial of IPI-504, the company's i.v.-administered Hsp90 chaperone inhibitor, in patients with advanced non-small cell lung cancer (NSCLC). Data reported show that IPI-504 demonstrated clinical activity in patients with NSCLC, in particular among patients with oncogenic anaplastic lymphoma kinase (ALK) gene rearrangements.

4 Jun 2010

Antiemetic-regimen with fosaprepitant injection provides similar protection against CINV as oral EMEND

Merck announced today results from a new non-inferiority trial of an antiemetic regimen containing fosaprepitant dimeglumine administered as a single intravenous (IV) 150-mg dose in combination with a 5-HT3 antagonist and dexamethasone compared with a three-day regimen of aprepitant with a 5-HT3 antagonist and dexamethasone for the prevention of chemotherapy-induced nausea and vomiting (CINV) in patients receiving a first cycle of cisplatin-based chemotherapy.

4 Jun 2010

Promising results of ABRAXANE for bladder cancer support efficacy of nab-driven chemotherapy

Abraxis BioScience, Inc. announced today that findings from a phase 1 randomized trial demonstrated that the nanoparticle albumin bound (nab®) driven chemotherapy, nab-paclitaxel (ABRAXANE® for Injectable Suspension; paclitaxel albumin protein-bound particles for injectable suspension) is well-tolerated and active in the second-line treatment of high-grade, non-muscle-invasive bladder cancer that has been refractory to standard intra-bladder infusion (intravesical) therapy.

4 Jun 2010

Life Technologies partners to create Genomic Cancer Care Alliance

Life Technologies Corporation today announced the creation of the Genomic Cancer Care Alliance to help people battling cancer gain access to treatment options found through analysis of their genomic information. Founding partners include Fox Chase Cancer Center, Scripps Genomic Medicine, and the Translational Genomics Research Institute (TGen). The announcement came during the Consumer Genetics Conference being held June 2-4 in Boston.

4 Jun 2010

Chemotherapy-induced amenorrhea improves survival in premenopausal women with early stage breast cancer

Chemotherapy-induced amenorrhea in premenopausal women being treated for early stage breast cancer was associated with significantly improved patient survival, according to a study published this week in the New England Journal of Medicine by the National Surgical Adjuvant Breast and Bowel Project (NSABP) in collaboration with leading US cancer centers and cooperative cancer research groups.

4 Jun 2010

China Medical Technologies fourth-quarter revenues down 29.3% to $25.7 million

China Medical Technologies, Inc., a leading China-based advanced in-vitro diagnostic company, today announced its unaudited financial results for the fourth fiscal quarter and the full fiscal year ended March 31, 2010.

4 Jun 2010

Wolverine Venture Fund participates in $8M series A round of financing for Delphinus Medical Technologies

The Wolverine Venture Fund (WVF), managed by The Samuel Zell & Robert H. Lurie Institute for Entrepreneurial Studies at the University of Michigan Ross School of Business, today announced participation in an $8 million series A round of financing for Delphinus Medical Technologies, Inc.

4 Jun 2010

Breast Cancer News and Research

Latest Breast Cancer News and Research

Eisai's eribulin mesylate improves median OS compared with TPC in pre-treated metastatic breast cancer patients

Bisphosphonates may cause poorer survival rate in women with early stage breast cancer: Study

bioTheranostics presents positive outcomes from CancerTYPE ID, Breast Cancer Index clinical studies

Incyte presents additional results from INCB7839 Phase I/II trial for HER2-positive metastatic breast cancer

Celldex Therapeutics reports mature data from CDX-011 Phase 1/2 study in advanced breast cancer

Phase Ib/II trial data for trastuzumab-DM1 in combination with pertuzumab presented at ASCO 2010

Positive results from new analyses of denosumab Phase 3 trials

Multiple study data on Agendia's MammaPrint, BluePrint, and ColoPrint assays to be presented at 2010 ASCO

New clinical research findings on oncology to be highlighted at ASCO 2010

USC to present promising new findings in cancer research at 2010 ASCO

Fox Chase Cancer Center announces first-in-human bi-specific HER2/HER3 pathway targeting antibody

Positive results from Phase 2, open-label ENCORE 303 trial to be presented at ASCO 2010

Bayer to present Phase I and II clinical trial data of Alpharadin in CRPC at 46th ASCO

Infinity announces Phase 2 clinical trial results of IPI-504 for NSCLC

Antiemetic-regimen with fosaprepitant injection provides similar protection against CINV as oral EMEND

Promising results of ABRAXANE for bladder cancer support efficacy of nab-driven chemotherapy

Life Technologies partners to create Genomic Cancer Care Alliance

Chemotherapy-induced amenorrhea improves survival in premenopausal women with early stage breast cancer

China Medical Technologies fourth-quarter revenues down 29.3% to $25.7 million

Wolverine Venture Fund participates in $8M series A round of financing for Delphinus Medical Technologies

Industry Focus eBook - Oncology (1st Edition) eBook

Real-time Raman monitoring for pharmaceutical hot melt extrusion

Synthetic Psychedelics: A Growing Public Health Concern

How the Vutara VXL simplifies single-molecule imaging

Breast Cancer News and Research

Latest Breast Cancer News and Research

Industry Focus eBook - Oncology (1st Edition) eBook

Real-time Raman monitoring for pharmaceutical hot melt extrusion

Synthetic Psychedelics: A Growing Public Health Concern

How the Vutara VXL simplifies single-molecule imaging

Newsletters you may be interested in